Cargando…
A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-f...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742090/ https://www.ncbi.nlm.nih.gov/pubmed/36518591 http://dx.doi.org/10.1097/BS9.0000000000000126 |
_version_ | 1784848458547462144 |
---|---|
author | Zhang, Hao Meng, Guoyu |
author_facet | Zhang, Hao Meng, Guoyu |
author_sort | Zhang, Hao |
collection | PubMed |
description | B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs. |
format | Online Article Text |
id | pubmed-9742090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97420902022-12-13 A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia Zhang, Hao Meng, Guoyu Blood Sci Review Article B-cell acute lymphoblastic leukemia (B-ALL) is a malignant tumor originating from B-lineage lymphoid precursor cells. The incidence of B-ALL is about 80% in childhood acute leukemia and 20% in adults. In recent years, with standardized treatment guided by risk stratification, the long-term disease-free survival rate of children is about 80%, while that of adults is less than 40%. However, the specific pathogenesis of the newly identified B-ALL and the targeted therapy strategies have not been vigorously investigated. In this review, we highlight the recent breakthroughs in mechanistic studies and novel therapeutic options in DUX4- and MEF2D-subtype B-ALLs. Lippincott Williams & Wilkins 2022-07-20 /pmc/articles/PMC9742090/ /pubmed/36518591 http://dx.doi.org/10.1097/BS9.0000000000000126 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Medical Association (CMA) and Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College (IHCAMS). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Review Article Zhang, Hao Meng, Guoyu A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia |
title | A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia |
title_full | A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia |
title_fullStr | A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia |
title_full_unstemmed | A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia |
title_short | A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia |
title_sort | typical bedside-to-bench investigation of leukemogenic driver mef2d fusion reveals new targeted therapy in b-cell acute lymphoblastic leukemia |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742090/ https://www.ncbi.nlm.nih.gov/pubmed/36518591 http://dx.doi.org/10.1097/BS9.0000000000000126 |
work_keys_str_mv | AT zhanghao atypicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia AT mengguoyu atypicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia AT zhanghao typicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia AT mengguoyu typicalbedsidetobenchinvestigationofleukemogenicdrivermef2dfusionrevealsnewtargetedtherapyinbcellacutelymphoblasticleukemia |